long intergenic non-protein coding RNA 1889Genealiases: []
Q-omics provides the consensus-scored LINC01889 profile across patient tissues and cancer cell-line models. LINC01889 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01889 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC01889 RNA expression shows 7,504 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where LINC01889 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01889 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01889 survival associations across molecular data types. LINC01889 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01889 RNA expression–survival associations across cancer types. High LINC01889 expression shows unfavorable associations in LUAD, SARC, UVM, LIHC and READ, but favorable associations in PRAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01889 RNA expression.
This table summarizes LINC01889 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01889. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01889 shows lower tumor expression in KIRC, KICH, KIRP, HNSC and COAD and higher tumor expression in CHOL. The KIRC box plot shows higher LINC01889 RNA expression in normal versus tumor tissue (log2 FC = −0.379, t-test p < 0.001).
This table shows molecular features associated with LINC01889 in patient tissues and cancer cell lines. In patient samples, LINC01889 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
